Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Polynovo ( (AU:PNV) ) has provided an update.
PolyNovo Limited has announced the appointment of Mr. Robert Douglas as a new Non-Executive Director, with a resolution for his election to be proposed at the upcoming Annual General Meeting. Mr. Douglas brings extensive experience from his previous role as Global Chief Operating Officer at ResMed, and his expertise is expected to enhance the board’s skillset and governance, benefiting the company and its stakeholders.
The most recent analyst rating on (AU:PNV) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Polynovo stock, see the AU:PNV Stock Forecast page.
More about Polynovo
PolyNovo Limited operates in the medical technology industry, focusing on the development and commercialization of innovative medical devices. The company is known for its advanced wound care solutions and has a market focus on expanding its presence in the global healthcare sector.
Average Trading Volume: 3,470,170
Technical Sentiment Signal: Sell
Current Market Cap: A$949.9M
For detailed information about PNV stock, go to TipRanks’ Stock Analysis page.